featured
Pertuzumab Plus Trastuzumab for HER2-Amplified Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pertuzumab Plus Trastuzumab for HER2-Amplified Metastatic Colorectal Cancer (MyPathway): An Updated Report From a Multicentre, Open-Label, Phase 2a, Multiple Basket Study
Lancet Oncol 2019 Mar 08;[EPub Ahead of Print], F Meric-Bernstam, H Hurwitz, KPS Raghav, RR McWilliams, M Fakih, A VanderWalde, C Swanton, R Kurzrock, H Burris, C Sweeney, R Bose, DR Spigel, MS Beattie, S Blotner, A Stone, K Schulze, V Cuchelkar, J HainsworthFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.